Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resista... (re treatable. For additional information...)

Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers

Date:11/21/2007

re treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with brostallicin in particular including, without limitation, the potential failure of brostallicin to prove safe and effective for treatment of solid tumors, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling brostallicin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer

Post Your Comments:

(Date:12/1/2009)...nc. today announced a collaborative research agree... at evaluating EpiVax’s proprietary Tregitop...mental immune responses to certain drugs. In the c...x Tregitope technology will be evaluated for its e...ics. , (Vocus) December 2...

(Date:12/1/2009).... 1 Aethlon Medical, Inc...it will present at the LD MICRO Conference on Thur...uxe Hotel in Los Angeles. Aethlon Medical,s Chairm...te overview and will provide an update on the comp...Hemopurifier®, a first-in-class artificial ad...

(Date:12/1/2009)...na, Dec. 1 /PRNewswire-Asia-FirstCall/ -- China Sk...he Company") (Nasdaq: CSKI ), a leading,fully int...ucing,over-the-counter drugs in the People,s Repub...pany has engaged Guangdong Mediacy Kind Medical De... its exclusive sales agent for the,Company,s AMI D...

(Date:12/1/2009)...wswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bull...d, biopharmaceutical company developing human vacc...iciency Virus) and other infectious agents, today ...oday is the 21st World AIDS Day and as we remember...HIV/AIDS pandemic, we remain focused and devoted t...

Breaking Biology Technology:EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 2 EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 3 Aethlon Medical to Present at LD MICRO Conference on December 3, 2009 2 China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 2 China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 3 GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 2 GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 3 GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 4 GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 5 GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 6

[0] EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology [0] Aethlon Medical to Present at LD MICRO Conference on December 3, 2009 [0] China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia [0] GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress

... Calif., Oct. 29 Sangamo,BioSciences, Inc. (Nasda...cial results and accomplishments., For the third ... a,consolidated net loss of $6.3 million, or $0.15..., or $0.11 per share, for the same period in 2007....ash equivalents and,investments of $59.5 million. ...

...Mass., Oct. 29 Aware, Inc. (Nasdaq:,AWRE), a lead...s software,announced today that its Board of Direc...inally authorized on August 28, 2007 to repurchase...o $5 million worth of shares of,the Company,s comm...cember,31, 2009 at prevailing market prices. The B...

...lion Net Revenues, $0.10 Net Income Per Share, SA...ies, Inc. (Nasdaq: VNUS ), a leading provider of ...nt of venous disease, today announced its,financia..., 2008., Net revenues for the third quarter of 20...7.5 million for the third quarter of 2007. Net,rev...

Sangamo BioSciences Reports Third Quarter 2008 Financial Results Aware, Inc. Announces Extension of Stock Repurchase Plan VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007

(Date:11/30/2009)...pings of gravy and dessert at the holiday table ar...ously thought. According to a new research report ... http://www.fasebj.org ), a diet that is high in f...timately cause our bodies to store too much fat. T... as the already difficult task of converting high-...

(Date:11/30/2009)...s available in German . , The DFG has appro...arch Centres as of 1 January 2010. This decision w...in Bonn. The new centres will initially be funded ...ition, 20 percent overhead funding for indirect co...ntres, research topics range from modern prosthese...

(Date:11/30/2009)...- The inaugural Global Conference on Systems & Ent... Washington, DC, focuses on the convergence of com...al importance to society. , The goal of the ...ivity around targeted complex systems, examined by...includes Critical Infrastructure Systems, includin...

[0] Happy holidays from the groaning board; Western diets turn on fat genes [0] DFG approves funding for 17 new collaborative research centers [0] First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4

...sts from around the world will convene at the Univ... key findings from the most ambitious effort ever ...tants in the Arctic and determine how they contrib...way in the vast, climate-sensitive region. , The ...ARCAT was conducted most intensively during two th...

...ands, May 26, 2009 There are several risk factors...scular dementia. Based on an increasing number of ...deficiency, an article in the current issue of the...lliam B. Grant, PhD of the Sunlight, Nutrition, an...rther investigation of possible direct or indirect...

...sen sharply in developed countries in the wake of ...Europeans live with the condition. Foot problems a...for diabetics, who are at risk of serious complica...lood supply to their feet. Both conditions can lea... they get infected and become gangrenous, can lead...

Other Biology News:Spring agricultural fires have large impact on melting Arctic 2 Spring agricultural fires have large impact on melting Arctic 3 Is vitamin D deficiency linked to Alzheimer's disease and vascular dementia? 2 Protective footwear for diabetics at a high-street price 2 Protective footwear for diabetics at a high-street price 3

Spring agricultural fires have large impact on melting Arctic Is vitamin D deficiency linked to Alzheimer's disease and vascular dementia?Protective footwear for diabetics at a high-street price

Amido Black 10B, CI 20470 from Research Organics, Inc.

Anti-Taste Receptor 2 (TR2) Polyclonal Antibody, Unconjugated from CHEMICON

Mouse Anti-Yersinia pestis Monoclonal Antibody, Unconjugated, Clone YPF19 from GeneTex

Anti-Human Ig Lambda-chain Monoclonal Antibody, Unconjugated, Clone ICO-16 from Cell Sciences

Biology Products:

Amido Black 10B, CI 20470 from Research Organics, Inc.Anti-Taste Receptor 2 (TR2) Polyclonal Antibody, Unconjugated from CHEMICON Mouse Anti-Yersinia pestis Monoclonal Antibody, Unconjugated, Clone YPF19 from GeneTex Anti-Human Ig Lambda-chain Monoclonal Antibody, Unconjugated, Clone ICO-16 from Cell Sciences

Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resista...(re treatable. For additional information...)